中国组织工程研究 ›› 2026, Vol. 30 ›› Issue (27): 7210-7218.doi: 10.12307/2026.798

• 植入物相关大数据分析 Implant related big data analysis • 上一篇    

整合CD4+ T细胞动态表达数量性状位点揭示肌少症免疫治疗靶点

金自成1,崔  凯2,李玉周1   

  1. 1河南师范大学体育学院,河南省新乡市  453007;2暨南大学医学院,广东省广州市  510632
  • 收稿日期:2025-09-10 接受日期:2025-12-15 出版日期:2026-09-28 发布日期:2026-05-26
  • 通讯作者: 李玉周,博士,教授,河南师范大学体育学院,河南省新乡市 453007
  • 作者简介:金自成,男,2000年生,2025年河南师范大学毕业,硕士,主要从事肌少症防治的新型干预策略研究。

Integration of CD4+ T cell dynamic expression of quantitative trait loci reveals immunotherapeutic targets for sarcopenia

Jin Zicheng1, Cui Kai2, Li Yuzhou1   

  1. 1College of Physical Education, Henan Normal University, Xinxiang 453007, Henan Province, China; 2Medical School, Jinan University, Guangzhou 510632, Guangdong Province, China
  • Received:2025-09-10 Accepted:2025-12-15 Online:2026-09-28 Published:2026-05-26
  • Contact: Li Yuzhou, PhD, Professor, College of Physical Education, Henan Normal University, Xinxiang 453007, Henan Province, China
  • About author:Jin Zicheng, MS, College of Physical Education, Henan Normal University, Xinxiang 453007, Henan Province, China

摘要:


文题释义:

动态表达数量性状位点:指基因组中调控基因表达水平的遗传变异位点,作用效应具有状态依赖性,即变异对靶基因表达的调控强度或方向随细胞状态动态演化(如活化阶段、代谢活性或谱系特异性表观遗传特征)而改变。
肌少症:是一种与增龄相关的慢性骨骼肌退行性疾病,主要特征为进行性骨骼肌质量减少、肌力下降及躯体功能减退,会增加患者跌倒、失能及代谢异常风险。

摘要
背景:肌少症是老年退行性疾病,目前缺乏特异性治疗药物。免疫细胞异常是肌少症的危险因素,CD4+ T细胞在骨骼肌修复与再生中发挥关键作用。以往研究主要采用全组织或血液表达数量性状位点数据鉴定药物靶点,难以揭示基因表达在特定细胞亚群及其动态激活状态下的调控效应。通过整合CD4+ T细胞的动态表达数量性状位点数据,探究基因表达对肌少症免疫细胞特异性及激活时间点依赖性的影响,为开发精准免疫干预策略提供依据。
目的:旨在揭示CD4+ T细胞亚群不同激活时相的基因表达与肌少症的特异性因果关联。
方法:基于SOSKIC等的研究(CD4+ T细胞动态表达数量性状位点数据,涵盖欧洲人群46种“细胞-激活状态”表达谱)、Database of Immune Cell Expression, eQTLs and Epigenomics平台(由美国国立卫生研究院主导,提供免疫细胞表达数量性状位点数据)、eQTLGen平台(由37家机构联合构建,提供欧洲人群血液特异性表达数量性状位点资源库)、The Genotype-Tissue Expression平台(由美国国立卫生研究院主导,整合了欧洲人群的49种人体组织数据,提供骨骼肌表达数量性状位点数据)与GWAS Catalog平台(由欧洲生物信息学研究所开发,提供全球范围内的基因组广泛关联研究数据),系统开展两样本孟德尔随机化分析。首先,以CD4+ T细胞动态表达数量性状位点为暴露,肌少症表型为结局进行孟德尔随机化分析,筛选候选基因。随后,利用免疫细胞、全血和骨骼肌组织表达数量性状位点数据进行孟德尔随机化分析验证基因特异性。同时,结合基于汇总数据的孟德尔随机化分析、异质性检验、共定位分析及差异基因表达分析(利用Gene Expression Omnibus数据库中编号为GSE111016的数据集)验证结果的可靠性。所有数据为公开汇总统计数据,符合伦理要求。所有分析严格筛选工具变量,并遵循观察性研究报告加强指南规范。
结果与结论:①基于汇总数据的孟德尔随机化分析和异质性检验结果显示,RAS致癌基因家族成员29(RAB29)、NADH:泛醌氧化还原酶核心亚基S3(NDUFS3)和基质金属蛋白酶24反义RNA基因(MMP24OS)与肌少症存在特异性因果关联;CD4+初始T细胞激活5 d时RAS致癌基因家族成员29的表达水平和CD4+记忆T细胞激活5 d时基质金属蛋白酶24反义RNA基因的表达水平与肌少症风险呈正向因果关联;初始T细胞激活16,40 h时NADH:泛醌氧化还原酶核心亚基S3的表达水平与肌少症风险呈负向因果关联;②共定位分析进一步证实,RAS致癌基因家族成员29、NADH:泛醌氧化还原酶核心亚基S3和基质金属蛋白酶24反义RNA基因的表达数量性状位点与肌少症的全基因组关联研究信号共享潜在因果变异;③差异基因表达分析结果显示,相较于健康对照组,肌少症组的NADH:泛醌氧化还原酶核心亚基S3表达水平显著下调,RAS致癌基因家族成员29和基质金属蛋白酶24反义RNA基因的表达水平在两组之间无显著差异,经验证NADH:泛醌氧化还原酶核心亚基S3为CD4+ T细胞中具有时序调控特性的潜在肌少症基因治疗靶点。该分析基于欧洲人群数据,未来可引入动态表达数量性状位点孟德尔随机化分析框架,开发与制定基于中国人群的T细胞功能时序精准调控干预策略。




中国组织工程研究杂志出版内容重点:人工关节;骨植入物;脊柱;骨折;内固定;数字化骨科;组织工程

关键词: ">肌少症, CD4+ T细胞, 表达数量性状位点, 全基">因组关联研究, 孟德尔随机化, 治疗靶点, 基于汇总数据的孟德尔随机化分析, 共定位分析

Abstract: BACKGROUND: Sarcopenia is a degenerative illness in the elderly, and there is currently a dearth of particular therapeutic medications. Abnormalities in immune cells are risk factors for sarcopenia. CD4+ T lymphocytes play a vital role in skeletal muscle repair and regeneration. Previous research generally used expression quantitative trait loci data from whole tissues or blood to identify pharmacological targets, making it difficult to uncover the regulatory effects of gene expression on distinct cell subpopulations and their dynamic activation states. This study integrates dynamic expression quantitative trait locus data of CD4+ T cells to evaluate the immune cell specificity and activation time-dependent impacts of gene expression on sarcopenia, providing a platform for the development of precise immune intervention techniques.
OBJECTIVE: To reveal the specific causal relationship between gene expression of different activation phases of CD4+ T cell subsets and sarcopenia.
METHODS: Based on the study by Soskic et al. (CD4+ T cell dynamic expression quantitative trait loci data, covering 46 “cell-activation state” expression profiles in European populations), the Database of Immune Cell Expression, eQTLs and Epigenomics platform (led by the National Institutes of Health, providing immune cell expression quantitative trait loci data), the eQTLGen platform (jointly constructed by 37 institutions, providing a resource library of blood-specific expression quantitative trait loci in European populations), the Genotype-Tissue Expression platform (led by the National Institutes of Health, integrating data from 49 human tissues in European populations, providing skeletal muscle expression quantitative trait loci data), and the GWAS Catalog platform (developed by the European Bioinformatics Institute, providing genome-wide association study data globally), a two-sample Mendelian randomization analysis was systematically conducted. First, Mendelian randomization analysis will be undertaken utilizing dynamic expression quantitative trait loci of CD4+ T cells as exposure and sarcopenia phenotype as outcome to screen for candidate genes. Subsequently, Mendelian randomization analysis was undertaken using expression quantitative trait loci data from immune cells, whole blood, and skeletal muscle tissue to validate gene specificity. Simultaneously, the reproducibility of the results was tested by combining Mendelian randomization analysis based on summary data, heterogeneity testing, colocalization analysis, and differential gene expression analysis (using the dataset # GSE111016 from the Gene Expression Omnibus database). All data are publicly aggregated statistics data and conform to ethical norms. All analyses properly screened instrumental variables and followed the STROBE standards for observational research.
RESULTS AND CONCLUSION: (1) After Mendelian randomization analysis and heterogeneity tests based on summary data, the results showed that RAB29, member RAS oncogene family (RAB29), NADH:ubiquinone oxidoreductase core subunit S3 (NDUFS3), and matrix metallopeptidase 24 antisense RNA (MMP24OS) had specific causal associations with sarcopenia. The expression level of RAB29 at 5 days post-activation of CD4+ naive T cells and the expression level of MMP24OS at 5 days post-activation of CD4+ memory T cells were positively causally associated with the risk of sarcopenia; the expression levels of NDUFS3 at 16 and 40 hours post-activation of naive T cells were negatively causally associated with the risk of sarcopenia. (2) Colocalization analysis further indicated that the expression quantitative trait loci of RAB29, NDUFS3, and MMP24OS had possible causative variations with the genome-wide association study signals for sarcopenia. (3) The results of differential gene expression analysis demonstrated that compared with the healthy control group, the expression level of NDUFS3 in the sarcopenia group was dramatically downregulated, but there was no significant change in the expression levels of RAB29 and MMP24OS between the two groups. It is confirmed that NDUFS3 is a possible gene therapy target for sarcopenia with temporal regulatory properties in CD4+ T cells. This analysis is based on data from the European population. In the future, a Mendelian randomization analysis framework for dynamic expression quantitative trait loci can be introduced to create and formulate precise intervention methods for the temporal control of T cell activity based on the Chinese population.

Key words: ">">font-size:12px, ">sarcopenia, CD4+ T cells, expression quantitative trait loci, genome-wide association study, Mendelian randomization, therapeutic targets, Mendelian randomization analysis based on pooled data, co-localization analysis

中图分类号: